To colonize the liver, colon cancer metastases must overcome hypoxia and other metabolic stress. Loo et al. now show that metastatic cells achieve this by decreasing miR-483 and miR-551a expression, which derepresses creatine kinase expression and allows energy to be captured from extracellular ATP through generation and import of phosphocreatine.
It has long been appreciated that cancer cells exhibit altered patterns of metabolism. The century-old observation of aerobic glycolysis-or, the Warburg Effect-has evolved into a more nuanced and context-specific understanding of how cancer cells reprogram their metabolism to meet the biosynthetic demands of rapid proliferation and overcome metabolic stress imposed by the microenvironment (Hanahan and Weinberg, 2011) . In this issue of Cell, in an elegant series of experiments, Loo et al. (2015) now demonstrate that downregulation of specific microRNAs (miRNAs) allows metastatic colon cancer cells to adapt metabolically to the harsh conditions in the liver by using a secreted liver metabolite to scavenge energy from the extracellular environment.
Several lines of evidence have suggested key roles for miRNAs in cancer progression and metabolism. Broad dysregulation of miRNA expression accompanies tumorigenesis (Volinia et al., 2006) , while loss of specific miRNAs is associated with promotion of metastasis both experimentally and clinically (Tavazoie et al., 2008) . miRNAs also regulate key enzymes important for maintaining the cancer metabolic program. For example, MYC enhances cancer glutamine metabolism in part by suppressing miR23a/b, leading to upregulation of the target glutaminase (Gao et al., 2009) , and mTOR activation promotes cancer glycolysis in part by suppressing miR-143 and upregulating its target, hexokinase 2 (Fang et al., 2012 The liver is considerably hypoxic and may have uneven levels of glucose in the interstitial space due to competition from neighboring hepatocytes. Because oxygen and glucose are key substrates for oxidative and glycolytic metabolism, colon cancer cells that metastasize to the liver experience metabolic stress. To overcome this stress, they capitalize on another metabolic feature of the liver-synthesis and secretion of creatine by hepatocytes. By suppressing miR-483 and miR-551a, colon cancer cells upregulate expression of their common target, CKB, and secrete it into the extracellular space, where it catalyzes formation of phosphocreatine from creatine and ATP. Phosphocreatine is then imported back into colon cancer cells through the transporter SLC6A8, where it is used to regenerate ATP needed for cellular functions (Figure 1) . Thus, by downregulating miR-483 and miR-551a, metastatic colon cancer cells are able to bypass intracellular glycolytic and oxidative metabolism by activating an alternative metabolic pathway, whereby they scavenge energy from the extracellular environment in the form of phosphocreatine and shuttle it into the cell.
Emerging evidence suggests that there may be a high degree of organ specificity in selection for metabolic traits enabling successful metastatic dissemination. While Loo et al. define a metabolic selection mechanism for colon cancer colonization of the liver, previous work has shown that fatty acids secreted by adipocytes in the omentum fuel growth of ovarian cancer metastases expressing higher levels of fatty acid-binding protein 4-a metabolic explanation for the predilection of ovarian cancer cells to metastasize to the omentum compared to neighboring tissues and organs (Nieman et al., 2011) . Other sites of metastasis may also have unique macrometabolic properties that enhance metastatic capacity of cancer cells with complementary metabolic proclivities. For instance, two common sites of metastasis, the brain and the lungs (Nguyen et al., 2009) , have high basal levels of glucose and oxygen perfusion, respectively, which may contribute to the high degree of metastatic colonization of these organs compared with others.
Notably, loss of miR-483 and miR-551a and increased expression of CKB, as well as SLC6A8, are observed in clinical samples of colon cancer liver metastases compared to primary colon tumors, suggesting a possible therapeutic opportunity. Indeed, the authors show that viral rescue of both miR-483 and miR-551a, as well as pharmacological inhibition of CKB with cyclocreatine, substantially decrease the extent of liver metastasis in a mouse model of metastatic colon cancer. Importantly, the reliance on phosphocreatine as an energy source for liver metastases may not be limited to colon cancer. Loo et al. show that pancreatic cancer cells, which also metastasize to the liver, suffer a similar decrease in metastatic capacity when CKB levels are depleted. Little has been reported on CKB levels in cancer, but it will be interesting to assess whether CKB levels correlate with a propensity to metastasize to the liver in other cancer subtypes.
The findings by Loo et al. suggest that targeting phosphocreatine metabolism may reduce liver metastasis in colon cancer patients. However, to successfully translate these findings to the clinic, it will be important to determine whether reliance of liver metastases on phosphocreatine metabolism changes at different stages of disease. Viral rescue of miR-483 and miR-551a and pharmacological inhibition of CKB reduce metastatic tumor burden when administered within 24 hr of injecting mice with colon cancer cells, suggesting that targeting phosphocreatine metabolism could be of clinical utility for patients with early disseminated disease to prevent development of liver metastases. But for patients with detectable secondary lesions, the value of targeting phosphocreatine metabolism remains unclear. Phosphocreatine metabolism may be most important for cancer cells to combat metabolic stress upon initial seeding of the liver, before expansion into a secondary tumor, when tumorinduced vasculature can deliver canonical metabolic substrates. Bolstering the idea that initial organ colonization and subsequent tumor expansion require different metabolic programs, circulating breast cancer cells were recently shown to exhibit increased oxidative metabolism compared to the primary tumor and secondary tumor outgrowths in the lungs (LeBleu et al., 2014) . Additionally, liver metastases in colorectal cancer patients exhibit glycolytic metabolism, according to PET studies using the glucose analog 18 F-fluorodeoxyglucose (Maffione et al., 2015) .
Together, these data suggest that metastatic cells may require a metabolic program focused on energy generation to survive metabolic stress upon initial colonization of a site, and may switch to a program using canonical metabolic substrates for growth post-vascularization. Understanding the dynamics of metabolic transitions between initial cancer dissemination, liver colonization, and metastatic outgrowth will aid selection of colon cancer patients who will benefit most from approaches to target phosphocreatine metabolism. Reduced miR-483 and miR-551a levels in metastatic colon cancer cells liberates expression of their mutual target, brain-type creatine kinase (CKB). CKB secreted by the metastatic cells in the liver phosphorylates extracellular creatine produced by hepatocytes using extracellular ATP to generate phosphocreatine. Extracellular phosphocreatine is imported into metastatic colon cancer cells by the transporter SLC6A8. Phosphocreatine is then used to regenerate the ATP needed to sustain the cell. This alternative metabolic pathway using extracellular phosphocreatine enables metastatic cells to survive metabolic stress imposed by the liver microenvironment during initial organ colonization, before tumor vascularization delivers canonical metabolic substrates.
